Search

Luis P Jodar

from Miami, FL
Age ~58
Get Report
Also known as:
Luis O
Related to:
Graciela JodarGraciela I Sarmiento, 68Ana L Jodar
Connected to:
Loyal W Jodar, 74Hanieh Jodat, 42Jeaneddy E Jodesty, 60Reginalde M Jodesty, 60Savika Jodhan, 42Tulsie Jodhan, 72Vanesa Jodharam, 27Thomas Jodian, 36Laetitia B Jodin, 41Cynthia A Jodis, 69

Luis Jodar Phones & Addresses

  • Miami, FL
  • Philadelphia, PA
  • Villanova, PA
  • Port Chester, NY
  • Cary, NC

Work

Company: Pfizer inc Mar 2012 Address: Collegeville, Pennsylvania Position: Vice president, vaccines, global, medicines development group and scientific affairs

Education

Degree: Post-Doctoral School / High School: Nagasaki and Osaka Universities 1993 to 1995 Specialities: Neuroimmunology

Skills

International Health • Program Development • Competitive Analysis • Strategic Alliances • Clinical Trials • Research • Medicine • Leadership • Non Profits • Infectious Diseases • Vaccines • Global Health • Epidemiology • Public Health • Clinical Research • Clinical Development • Pharmaceutical Industry • Life Sciences • Medical Affairs

Languages

English • French • Japanese • Spanish

Industries

Pharmaceuticals

Resumes

Resumes

Luis Jodar Photo 1

Chief Medical Officer, Vaccines

View page
Location:
Philadelphia, PA
Industry:
Pharmaceuticals
Work:
Pfizer Inc - Collegeville, Pennsylvania since Mar 2012
Vice President, Vaccines, Global, Medicines Development group and Scientific Affairs
Pfizer Pharmaceuticals May 2010 - Mar 2012
Head of Vaccines, Medical Affairs, Emerging Markets
Wyeth Pharmaceuticals May 2008 - May 2010
Executive Director Clinical and Scientific Affairs Asia Pacific
International Vaccine Institute Jul 2002 - May 2008
Deputy Director General
World Health Organization May 1996 - Jul 2002
Scientist, Head of Meningococcal Vaccines
Education:
Nagasaki and Osaka Universities 1993 - 1995
Post-Doctoral, Neuroimmunology Universidad Complutense de Madrid 1990 - 1992
PhD, Clinical pharmacology and International Health Universidad Complutense de Madrid 1985 - 1990
Pharm.D, Pharmaceutical and Biological Sciences
Skills:
International Health
Program Development
Competitive Analysis
Strategic Alliances
Clinical Trials
Research
Medicine
Leadership
Non Profits
Infectious Diseases
Vaccines
Global Health
Epidemiology
Public Health
Clinical Research
Clinical Development
Pharmaceutical Industry
Life Sciences
Medical Affairs
Languages:
English
French
Japanese
Spanish

Publications

Us Patents

Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens, Kits Comprising The Same And Uses Thereof

View page
US Patent:
20190070282, Mar 7, 2019
Filed:
Sep 25, 2018
Appl. No.:
16/140934
Inventors:
- New York NY, US
Luis Pascual Jodar Martin-Montalvo - Villanova PA, US
Raul Enrique Isturiz - Norristown PA, US
Ralf Rene Reinert - Bad Soden am Taunus, DE
International Classification:
A61K 39/09
A61K 47/64
A61K 39/385
A61K 39/00
Abstract:
The present invention relates to new immunogenic compositions comprising conjugated capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a serotype not found in PREVNAR, SYNFLORIX and/or PREVNAR 13. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.

Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens, Kits Comprising The Same And Uses Thereof

View page
US Patent:
20170021006, Jan 26, 2017
Filed:
Jul 20, 2016
Appl. No.:
15/214693
Inventors:
- New York NY, US
Luis Pascual Jodar Martin-Montalvo - Villanova PA, US
Raul Enrique Isturiz - Norristown PA, US
Ralf Rene Reinert - Bad Soden am Taunus, DE
International Classification:
A61K 39/09
A61K 47/48
Abstract:
The present invention relates to new immunogenic compositions comprising conjugated capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a serotype not found in PREVNAR, SYNFLORIX and/or PREVNAR 13. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
Control profile
Luis P Jodar from Miami, FL, age ~58 Get Report